Skip to content
Home/Companies/Biotech/HyTest

HyTest

Biotech·Finland·Exited 2021·Held 3yr
Entry
2018
Hold
3yr
Exit
2021

Who owns HyTest?

HyTest was owned by Summa Equity through Summa Equity Fund I (2017 vintage) from 2018 to 2021, exited via Trade Sale.

Buyer identity available on Pro.

Hand-verified · updated 2026-08-18

Summa Equity
Investor
Summa Equity
Summa Equity Fund I · 2017 · Buyout

Key facts

HQFinland
SectorBiotech
StatusAcquired
Exit Type
Trade Sale
Buyer
MOIC
–
Exit Year
2021

More from Summa Equity Fund I

Other portfolio companies in the same fund.

Lakers Group
Exited 2021
IndustrialsSweden· 2018
to
LOGEX
Logex
Active
HealthTechNetherlands· 2018
Documaster
Exited 2025
SoftwareNorway· 2017
to
Lin Education
Exited 2019
EdTechSweden· 2017
to
Milarex
Exited 2025
FoodTechNorway· 2017
to
Norsk Gjenvinning
Active
Business ServicesNorway· 2017

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS
Track HyTest

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Who could buy HyTest?

7 strategic and 113financial buyers match this company's sector and geography profile, ranked from verified European deal history.

Find likely buyers

Get the full record on HyTest.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyer and MOIC on this deal (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue